Clinical, Laboratory, and Molecular Characteristics of Inherited Vitamin K-Dependent Coagulation Factors Deficiency.

IF 3.6 2区 医学 Q2 HEMATOLOGY Seminars in thrombosis and hemostasis Pub Date : 2024-11-04 DOI:10.1055/s-0044-1792031
Salvatore Perrone, Simona Raso, Mariasanta Napolitano
{"title":"Clinical, Laboratory, and Molecular Characteristics of Inherited Vitamin K-Dependent Coagulation Factors Deficiency.","authors":"Salvatore Perrone, Simona Raso, Mariasanta Napolitano","doi":"10.1055/s-0044-1792031","DOIUrl":null,"url":null,"abstract":"<p><p>Vitamin K-dependent coagulation factors deficiency (VKCFD) is a rare autosomal recessive genetic disease characterized by impaired levels of multiple coagulation factors (II, VII, IX, and X) and natural anticoagulants (proteins C and S). VKCFD is part of familial multiple coagulation factor deficiencies, reporting overall 50 affected families thus far. Disease manifestations are quite heterogeneous, bleeding symptoms may vary, and even, although generally mild, some patients may succumb to fatal outcomes. VKCFD diagnosis may be delayed because the disease phenotype simulates the most frequently acquired deficiencies of vitamin K. First-line coagulation assays, prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT), are both prolonged; mixing test typically normalizes the clotting times; and vitamin K-dependent coagulation factors will be variably decreased. Molecularly, VKCFD is associated with mutations in <i>γ-glutamyl-carboxylase</i> (<i>GGCX</i>) or <i>vitamin K epoxide reductase</i> complex subunit 1 (<i>VKORC1</i>) genes. Vitamin K is involved not only in the biosynthesis of coagulation proteins but also in bone metabolism and cell proliferation. Therapeutic options are based on vitamin K supplementation, coagulation factors (prothrombin complex), and fresh frozen plasma, in case of severe bleeding episodes. Two case studies here illustrate the diagnostic challenges of VKCFD: case 1 depicts a woman with a history of bleeding episodes, diagnosed, only in her third decade of life with inherited homozygous <i>GGCX</i> gene mutation. Case 2 shows a man with an acquired vitamin K deficiency caused by Crohn's disease. Better understanding of <i>GGCX</i> and <i>VKORC1</i> mutations aids in prognosis and treatment planning, with emerging insights suggesting potential limitations in the effectiveness of vitamin K supplementation in certain mutations.</p>","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in thrombosis and hemostasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/s-0044-1792031","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Vitamin K-dependent coagulation factors deficiency (VKCFD) is a rare autosomal recessive genetic disease characterized by impaired levels of multiple coagulation factors (II, VII, IX, and X) and natural anticoagulants (proteins C and S). VKCFD is part of familial multiple coagulation factor deficiencies, reporting overall 50 affected families thus far. Disease manifestations are quite heterogeneous, bleeding symptoms may vary, and even, although generally mild, some patients may succumb to fatal outcomes. VKCFD diagnosis may be delayed because the disease phenotype simulates the most frequently acquired deficiencies of vitamin K. First-line coagulation assays, prothrombin time/international normalized ratio (PT/INR) and activated partial thromboplastin time (aPTT), are both prolonged; mixing test typically normalizes the clotting times; and vitamin K-dependent coagulation factors will be variably decreased. Molecularly, VKCFD is associated with mutations in γ-glutamyl-carboxylase (GGCX) or vitamin K epoxide reductase complex subunit 1 (VKORC1) genes. Vitamin K is involved not only in the biosynthesis of coagulation proteins but also in bone metabolism and cell proliferation. Therapeutic options are based on vitamin K supplementation, coagulation factors (prothrombin complex), and fresh frozen plasma, in case of severe bleeding episodes. Two case studies here illustrate the diagnostic challenges of VKCFD: case 1 depicts a woman with a history of bleeding episodes, diagnosed, only in her third decade of life with inherited homozygous GGCX gene mutation. Case 2 shows a man with an acquired vitamin K deficiency caused by Crohn's disease. Better understanding of GGCX and VKORC1 mutations aids in prognosis and treatment planning, with emerging insights suggesting potential limitations in the effectiveness of vitamin K supplementation in certain mutations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
遗传性维生素 K 依赖性凝血因子缺乏症的临床、实验室和分子特征。
维生素 K 依赖性凝血因子缺乏症(VKCFD)是一种罕见的常染色体隐性遗传病,其特征是多种凝血因子(II、VII、IX 和 X)和天然抗凝剂(蛋白质 C 和 S)水平受损。VKCFD 是家族性多种凝血因子缺乏症的一部分,迄今已报告了 50 个受影响的家族。这种疾病的表现多种多样,出血症状也各不相同,甚至,尽管一般情况下症状较轻,但有些患者可能会致命。一线凝血测定,凝血酶原时间/国际标准化比率(PT/INR)和活化部分凝血活酶时间(aPTT)都会延长;混合试验通常会使凝血时间正常化;维生素 K 依赖性凝血因子会出现不同程度的减少。从分子角度看,VKCFD 与γ-谷氨酰-羧化酶(GGCX)或维生素 K 环氧化物还原酶复合物亚基 1(VKORC1)基因突变有关。维生素 K 不仅参与凝血蛋白的生物合成,还参与骨代谢和细胞增殖。治疗方法包括补充维生素 K、凝血因子(凝血酶原复合物)和新鲜冰冻血浆,以防严重出血。这里的两个病例研究说明了 VKCFD 在诊断方面的挑战:病例 1 描述了一名有出血发作史的妇女,在她生命的第三个十年才被诊断出患有遗传性同卵 GGCX 基因突变。病例 2 显示的是一名因克罗恩病导致维生素 K 缺乏的男性患者。更好地了解 GGCX 和 VKORC1 基因突变有助于预后判断和治疗计划的制定,新的研究表明,在某些基因突变的情况下,维生素 K 补充剂的效果可能会受到限制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Seminars in thrombosis and hemostasis
Seminars in thrombosis and hemostasis 医学-外周血管病
CiteScore
8.80
自引率
21.10%
发文量
132
审稿时长
6-12 weeks
期刊介绍: Seminars in Thrombosis and Hemostasis is a topic driven review journal that focuses on all issues relating to hemostatic and thrombotic disorders. As one of the premiere review journals in the field, Seminars in Thrombosis and Hemostasis serves as a comprehensive forum for important advances in clinical and laboratory diagnosis and therapeutic interventions. The journal also publishes peer reviewed original research papers. Seminars offers an informed perspective on today''s pivotal issues, including hemophilia A & B, thrombophilia, gene therapy, venous and arterial thrombosis, von Willebrand disease, vascular disorders and thromboembolic diseases. Attention is also given to the latest developments in pharmaceutical drugs along with treatment and current management techniques. The journal also frequently publishes sponsored supplements to further highlight emerging trends in the field.
期刊最新文献
The Role of Platelets in Atherosclerosis: A Historical Review. Publisher's Note. Acquired Hemophilia A after Tislelizumab Treatment in a Patient with Right Lung Squamous Cell Carcinoma. Clinical, Laboratory, and Molecular Characteristics of Inherited Vitamin K-Dependent Coagulation Factors Deficiency. Laboratory and Molecular Diagnosis of Factor XI Deficiency.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1